Scienture vs Exicure
SCNX and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SCNX and XCUR compare
Scienture is the larger company, worth 18 times as much as Exicure ($123M against $7.0M).
Exicure scores higher on the StockData Score (4 against 3 for Scienture), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SCNX | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | $123M | $7.0M |
| Share price | $2.99 | $1.07 |
| Change, 1 year | −82.2% | −70.7% |
| Change, 5 years | −99.8% | −98.6% |
| Beta (5Y) | 1.07 | −0.97 |
| Employees | 8 | 8 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.9× (better) | 7.2× |
| Growth | ||
| Revenue growth, 5Y average | −52.1% | – |
| Profitability | ||
| Return on equity | −53.5% (better) | −168% |
| Return on invested capital | −47.3% (better) | −4377% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −13.1× | – |
| Current ratio | 3.04 (better) | 0.56 |
| Altman Z-score | 0.31 (better) | −27.36 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 2.1% |
| Held by insiders | 16.6% | 92.6% |
| Insider net buying, 12 months | – | −$11.6M |
| Short interest, % of float | 0.34% | 10.8% |
Go deeper
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.